SEROPREVALENCE OF HUMAN LYMPHOTROPIC-T VIRUS TYPE-I OR TYPE-II IN SEXUALLY-TRANSMITTED DISEASE CLINIC PATIENTS IN THE USA

被引:24
|
作者
KHABBAZ, RF
DOUGLAS, JM
JUDSON, FN
SPIEGEL, RA
STLOUIS, ME
WHITTINGTON, W
HARTLEY, TM
LAIRMORE, M
KAPLAN, JE
机构
[1] DENVER DEPT PUBL HLTH,DENVER,CO
[2] UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262
[3] CTR DIS CONTROL,CTR INFECT DIS,AIDS PROGRAM,ATLANTA,GA 30333
[4] CTR DIS CONTROL,DIV FIELD SERV,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30333
[5] CTR DIS CONTROL,CTR PREVENT SERV,DIV SEXUALLY TRANSMITTED DIS,ATLANTA,GA 30333
关键词
D O I
10.1093/infdis/162.1.241
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Serum specimens from patients attending sexually transmitted disease (STD) clinics in Denver and several southeastern US cities were tested for antibody to human T-Iymphotropic virus type lor II (HTLV-I/II). In Denver, 8 (2.1%) of 384 patients with a history of intravenous (IV) drug use, versus none of 201 non-IV-drug users, were HTLV-I/II seropositive. Only 2 (0.18%) of 1095 STD clinic patients from the southeastern USA had antibodies to HTLV-I/II. These data document a low prevalence of HTLV-I/II in STD clinic patients from the southeastern USA and confirm that IV drug use is an important risk factor for HTLV-I/II in the USA. © 1990 by The University of Chicago.
引用
收藏
页码:241 / 244
页数:4
相关论文
共 50 条
  • [1] INFECTION WITH HUMAN T-LYMPHOTROPIC VIRUS TYPE-I AND TYPE-II IN SEXUALLY-TRANSMITTED DISEASE CLINICS IN BALTIMORE AND NEW-ORLEANS
    WIKTOR, SZ
    CANNON, RO
    ATKINSON, WL
    LUTZ, B
    HOOK, EW
    BLATTNER, WA
    QUINN, TC
    JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (05) : 920 - 924
  • [2] HUMAN LYMPHOTROPIC-T VIRUS TYPE-I NEUROTROPISM
    ROMAN, GC
    ROMAN, LN
    OSAME, M
    PROGRESS IN MEDICAL VIROLOGY, 1990, 37 : 190 - 210
  • [3] SPASTIC PARAPARESIS AND DUAL EXPOSURE TO HUMAN LYMPHOTROPIC-T VIRUS TYPE-I AND HUMAN LYMPHOTROPIC-T VIRUS TYPE-IV
    HUGON, J
    DUMAS, M
    VALLAT, JM
    DENIS, F
    PIQUEMAL, M
    GIORDANO, C
    BARIN, F
    ANNALS OF INTERNAL MEDICINE, 1987, 107 (01) : 111 - 111
  • [4] SEROLOGIC DIFFERENTIATION OF HUMAN LYMPHOTROPIC-T VIRUS TYPE-I FROM TYPE-II INFECTION BY SYNTHETIC PEPTIDE IMMUNOASSAYS
    ROBERTS, CR
    MITRA, R
    HYAMS, K
    BRODINE, SK
    LAL, RB
    JOURNAL OF MEDICAL VIROLOGY, 1992, 36 (04) : 298 - 302
  • [5] THE EPIDEMIOLOGY OF HUMAN T-LYMPHOTROPIC VIRUS TYPE-I AND TYPE-II
    KAPLAN, JE
    KHABBAZ, RF
    REVIEWS IN MEDICAL VIROLOGY, 1993, 3 (03) : 137 - 148
  • [6] HUMAN LYMPHOTROPIC-T VIRUS TYPE-I AND POLYMYOSITIS AND DERMATOMYOSITIS IN JAPAN
    NISHIKAI, M
    SATO, A
    ARTHRITIS AND RHEUMATISM, 1991, 34 (06): : 791 - 792
  • [7] INFECTION WITH THE HUMAN LYMPHOTROPIC-T VIRUS TYPE-I - A REVIEW FOR CLINICIANS
    DIXON, AC
    DIXON, PS
    NAKAMURA, JM
    WESTERN JOURNAL OF MEDICINE, 1989, 151 (06) : 632 - 637
  • [8] IMPLICATIONS OF HUMAN T-LYMPHOTROPIC VIRUS TYPE-I AND TYPE-II TESTING IN DONORS AND PATIENTS
    FISCHER, HE
    LICHTIGER, B
    GLASSMAN, AB
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 1995, 25 (05) : 373 - 380
  • [9] PHARMACOLOGICAL INHIBITION OF INVITRO INFECTIVITY OF HUMAN LYMPHOTROPIC-T VIRUS TYPE-I
    MATSUSHITA, S
    MITSUYA, H
    REITZ, MS
    BRODER, S
    JOURNAL OF CLINICAL INVESTIGATION, 1987, 80 (02) : 394 - 400
  • [10] ARTHRITIS IN PATIENTS INFECTED WITH HUMAN LYMPHOTROPIC-T VIRUS TYPE-I - CLINICAL AND IMMUNOPATHOLOGIC FEATURES
    SATO, K
    MARUYAMA, I
    MARUYAMA, Y
    KITAJIMA, I
    NAKAJIMA, Y
    HIGAKI, M
    YAMAMOTO, K
    MIYASAKA, N
    OSAME, M
    NISHIOKA, K
    ARTHRITIS AND RHEUMATISM, 1991, 34 (06): : 714 - 721